Triplet Combination of Cytotoxics as First-line Treatment for Metastatic Gastric Cancer
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This parallel, randomized, open-label study will evaluate the effect on overall survival of
irinotecan on oxaliplatin and 5-fluorouracil (5-FU) in patients with HER2-negative and pMMR
metastatic gastric cancer. Irinotecan will be administered as intravenous infusion of 150
mg/m2 every 2 weeks. Oxaliplatin will be given 85 mg/m2 and 5-FU will be given 400mg/m2 iv
and 2400mg/m2 civ 48 hours fortnightly. Treatment will continue until disease progress or
untolerable toxicity appears. The target sample size is 350-400 patients.